PPD Sees Biomarkers As Key To Drug Development
This article was originally published in The Pink Sheet Daily
The company is seeking to accelerate its acquisition of SurroMed's biomarker discovery services business, with the goal of closing a deal in the first quarter of 2005. FDA has placed biomarker development "near the top" of its "Critical Path" initiative, PPD CEO Eshelman notes.
You may also be interested in...
An FDA working group will develop guidance on the use of imaging to speed drug development. Locating the biomarkers will require coordination between manufacturers and the imaging industry.
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar